Navigation Links
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Date:11/25/2008

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response in the International Normalized Ratio (INR), a routine laboratory test used to assess the level of anticoagulation (blood-thinning).

"Single doses of PCI-27483 reliably and quickly achieved therapeutic levels of anticoagulation without adverse effects in this initial trial," said James Lowder, M.D., Vice President, Clinical Development for Pharmacyclics. "The ability to achieve precise levels of anticoagulation that can be readily measured differentiates PCI-27483 from other available anticoagulants. The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, has been implicated both in the progression of solid tumors and the increased incidence of venous thromboembolic events observed in many malignancies. Up-regulation of tissue factor expression is observed in pancreatic, lung, and breast cancer, and is associated with a worsened prognosis."

In the recently completed study, PCI-27483 increased the INR with minimal intra-subject variation and a half-life of ten hours. At the highest subcutaneous dose of PCI-27483 evaluated, a mean (+/-standard error) peak INR of 2.72 (+/- 0.24) was achieved one to two hours post-dosing. The trial further established doses of PCI-27483, which upon repeated dosing are expected to maintain the INR in the range of 2.0 to 3.0, the target window for treatment and prevention of thromboembolic events (i.e., formation of blood clots).


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements ... the SAM Junctional Tourniquet.  Photo ... Medical Products announced today that it has begun ... a potential issue with a clip used to ... application of the SAM Junctional Tourniquet (SJT).  The ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- ... release financial results for the fiscal fourth quarter and full ... The company will host a conference call for investors on ... may access the live call by dialing 877-941-9205 (within the ...
... , HARRISBURG, Pa., Nov. 20 The Department of Health ... that did not have previous access to the vaccine. , A total ... hours are from 2 p.m. to 8 p.m. Hours on Saturday, Nov. ... the clinics will operate from 2 p.m. to 8 p.m. , ...
Cached Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:9/1/2014)... Texas (PRWEB) September 02, 2014 “Australia ... data on the Australia Hernia Repair market. The report ... units) and average prices (in US dollars) within market ... Meshes and Synthetic 3D Meshes) ,     Composite Meshes ... to a surgical operation for the correction of a ...
(Date:9/1/2014)... with action and sound may be bad for your ... grapes while watching an excerpt from a Hollywood action ... Television has been blamed for helping Americans to gain ... focus of why has been on the medium and ... that can cause people to eat more, including reading, ...
(Date:9/1/2014)... Reinberg HealthDay Reporter ... head-to-head comparison, an experimental drug was more effective than ... failure patients. According to the study authors, the ... of the new drug, dubbed LCZ696. In ... medication, enalapril (Vasotec), either died or were hospitalized due ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 Liver is ... one vital organ that helps the body in barring itself ... a store of energy. Liver also plays many important functions ... iron and glucose. , Many illnesses can affect the ... under the rib cage on the right side of the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 More than ... added to a federal litigation that continues to progress ... Bernstein Liebhard LLP reports. , A federal Case ... filed over the widely-used cholesterol medication by plaintiffs who ... According to claims, Pfizer Inc. failed to adequately warn ...
Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3
... The infant mortality rate in Orissa would continue to soar ... Suni Naik’s family is still trying to recover after losing ... delivery. // ,Speaking at Talchampei village in tribal-dominated Keonjhar ... They suffered from fever. I took Rs.1,000 from a moneylender ...
... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
... it has been shown that tomato juice prevented emphysema in ... of the lung-destroying disease. // ,The lung protective ... ,This study appears to be the first to link tomato ... by the researchers, 'We can't simply accept that these results ...
... is greatly increased if an individual has a variant form ... tongue // . The taste receptor gene, called TAS2R16 is ... Washington University School of Medicine have studied more than 262 ... family participated in a study called Collaborative Study of the ...
... his team from University of California, San Francisco using ... sickle cell anemia // in bioengineered mice with healthy ... genes, after therapy it was found that the replaced ... published their work in the Journal Proceedings of the ...
... Department of Health and Human Services reported that very little ... of the illness (bird flu) // . The infection in ... avian influenza. ,Hence to prevent the global pandemic ... of an occurrence of a global pandemic. The government ...
Cached Medicine News:Health News:Poverty Claims Valuable Lives Of Children In Orissa 2Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2